In:
Oncology, S. Karger AG, Vol. 81, No. 5-6 ( 2011), p. 298-305
Abstract:
〈 i 〉 Objective: 〈 /i 〉 This study reports the efficacy and safety of zoledronic acid (ZOL) in preventing bone loss in postmenopausal patients receiving an aromatase inhibitor (AI) following tamoxifen. 〈 i 〉 Methods: 〈 /i 〉 Postmenopausal patients with stage I–III hormone receptor-positive breast cancer who received tamoxifen for 2.5–3 years were randomized to receive letrozole (2.5 mg/day) with (n = 47) or without (n = 43) ZOL (4 mg i.v. every 6 months) for 2 years. The primary endpoint was percent change from baseline in lumbar spine (LS) bone mineral density (BMD) up to 60 months. 〈 i 〉 Results: 〈 /i 〉 Ninety patients (86 evaluable) with a median age of 59 years (42.9–83.6), 50/86 of whom had previously been treated with chemotherapy, were followed for a median time of 41.4 months. While the control group showed a significant decrease in LS T-score (p = 0.0005), the ZOL group presented an increase over time (p = 0.0143). Change over time in LS T-score was significantly different between groups, favoring ZOL (p 〈 0.0001 at 24 and 48 months). No fractures, renal dysfunction or osteonecrosis of the jaw were reported. The toxicity profile was similar to those previously reported for each drug. 〈 i 〉 Conclusion: 〈 /i 〉 The addition of ZOL to letrozole was safe and efficacious in maintaining LS BMD in postmenopausal patients with hormone receptor-positive breast cancer and who were receiving letrozole following 2.5–3 years of tamoxifen.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2011
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
